A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumours or Lymphoma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2017
Price : $35 *
At a glance
- Drugs NC 4016 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 19 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Jul 2016 Planned number of patients changed from 30 to 40.
- 05 Dec 2013 New sourc identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01999491).